Par to pay $153M in pricing lawsuit settlement
Par Pharmaceutical has agreed to pay $153 million to settle drug pricing lawsuits alleging the company caused government entities to pay inflated reimbursements. Report
THE LIBRARY: WEBINAR
Getting the most PoC data in Phase I cancer studies
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Latest Commentary
EVENTS
- MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
- Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
- What's your BIO?June 18-21, 2012 — Boston, MA
Press Releases
- Antibodies in breast milk may fight HIV
- AdvaMed Praises Senate Passage of Medical Device User Fee Reauthorization
- Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
- Lucigen Corporation Awarded $2.8M SBIR Grant for Point of Care Diagnostics
- Blueprint Medicines Welcomes Fidelity Biosciences to Investor Syndicate
- More Press Releases
Featured Jobs
-
Quality Assurance Scientist Job
Yoh - Brea, CA, USA -
Biostatistician (Entry Level) - Permanent Job
Yoh - Tarrytown, NY, USA -
Oncology Knowledge Lead
Merck - Boston, MA -
Supervisor, QC Chemistry - 3rd Shift Job
Celgene Corporation - Phoenix, AZ, US -
Clinical Research Associate / CRA Virology Job
Yoh - Danbury, CT, USA
Comments